No analyst coverage available for this stock.
Atomo Diagnostics Ltd is an Australian medical device company specializing in integrated rapid diagnostic test (RDT) devices for the global healthcare market. The company’s patented technology streamlines testing procedures, making them accessible for both professional users and untrained individuals, with applications in point-of-care and at-home settings. Atomo Diagnostics has commercialized products targeting infectious diseases such as HIV, COVID-19, and viral versus bacterial differentiation, as well as female health diagnostics. Its flagship offerings include the Atomo HIV Self-Test and the AtomoRapid platform, recognized for their ease of use, reliability, and high performance. The company operates in the healthcare equipment sector, serving markets worldwide through direct sales and partnerships. Atomo Diagnostics Ltd is listed on the CHI-X Market Australia – Limit Venue, an alternative trading platform that provides competitive pricing and efficient access to Australian equities. The company’s innovations support improved healthcare outcomes and expanded access to diagnostic testing, particularly in underserved regions.